Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke.
Accumulating data suggest that matrix metalloproteinases (MMPs), in particular MMP-2 and MMP-9, are deleterious after acute ischaemic stroke. A beneficial effect of MMPs in the repairing phases of cerebral ischaemia has also been proposed. This study investigated the relationship between MMP-2 and MMP-9 and stroke subtypes, clinical recovery and haemorrhagic transformation (HT). We measured MMP-9 and MMP-2 plasma levels in 29 patients with ischaemic stroke at days one and seven. MMP-2 levels increased only in lacunar strokes, whilst MMP-9 increased only in patients with more severe stroke. Basal MMP-2 levels were higher in patients with stable or recovering symptoms whilst MMP-9 values at day seven were correlated with worse clinical outcome. No differences related to the presence of HT were found. This study sustains a different behaviour of MMPs after ischaemic stroke. MMP-2 seems to be expressed early and related to better outcome, whilst MMP-9 seems to be late and related to more severe stroke.
Lucivero
V
V
Department of Neurological and Psychiatric Sciences, University of Bari, Piazza G. Cesare 12, 1-70124, Bari, Italy.
Prontera
M
M
Mezzapesa
D M
DM
Petruzzellis
M
M
Sancilio
M
M
Tinelli
A
A
Di Noia
D
D
Ruggieri
M
M
Federico
F
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood*; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D020521:Stroke / Q000097:blood*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood
D019715:Tissue Inhibitor of Metalloproteinase-1; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9
Stroke. 2001 Dec 1;32(12):2762-7
11739970
Eur J Neurosci. 2003 Sep;18(6):1507-17
14511330
Stroke. 1993 Jan;24(1):35-41
7678184
Free Radic Biol Med. 2005 Jul 1;39(1):71-80
15925279
Stroke. 1988 May;19(5):604-7
3363593
Eur Neurol. 2006;55(1):11-5
16432302
J Cereb Blood Flow Metab. 2003 Dec;23(12):1403-7
14663335
Circulation. 2003 Feb 4;107(4):598-603
12566373
J Neurosci. 2001 Oct 1;21(19):7724-32
11567062
Stroke. 1998 Oct;29(10):2189-95
9756602
Circ Res. 2003 May 2;92(8):827-39
12730128
Lancet. 1991 Jun 22;337(8756):1521-6
1675378
Stroke. 2003 Sep;34(9):2165-70
12907822
Stroke. 2005 Jul;36(7):1415-20
15947272
Glia. 2002 Sep;39(3):279-91
12203394
CNS Drugs. 2001;15(11):819-29
11700147
Glia. 2005 Jun;50(4):329-39
15846802
Cerebrovasc Dis. 2005;20(3):141-51
16088108
Clin Chem Lab Med. 2006;44(4):428-34
16599837
Stroke. 1989 Jul;20(7):864-70
2749846
Lancet Neurol. 2005 Sep;4(9):530
16136704
Neurosci Lett. 1997 Nov 28;238(1-2):53-6
9464653
Nat Med. 2006 Apr;12(4):441-5
16565723
Stroke. 2003 Jan;34(1):40-6
12511748
Stroke. 2001 Aug;32(8):1759-66
11486102